<DOC>
	<DOCNO>NCT00262665</DOCNO>
	<brief_summary>The purpose study test candidate drug , Org 24448 , phase II clinical trial adult patient moderately treatment-resistant unipolar major depressive disorder .</brief_summary>
	<brief_title>Randomized , Placebo-controlled Trial AMPAkine Major Depressive Disorder</brief_title>
	<detailed_description>Major depressive disorder ( MDD ) common , severe , chronic often life-threatening illness . Major depression contribute significant morbidity mortality . Available pharmacotherapies major depression suboptimal term speed onset , efficacy , tolerability . Current medication severe , chronic mood disorder base pathophysiological model illness , rather variation monoaminergic-based therapy . Org 24448 represent new treatment approach depression , potentiate AMPA receptor subfamily ionotropic glutamate receptor . This drug show antidepressant feature preclinical model , well cognitive-enhancing quality .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Clinical Diagnosis MDD Have respond adequate trial one antidepressant current episode complete antidepressant trial due intolerance â‰¤3 antidepressant medication current previous episode Presence psychotic feature , OCD , drug alcohol dependency precede 3 month</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>